New treatments in type 2 diabetes: A focus on the incretin-based therapies

Clinical Endocrinology

Volumn 70, Issue 3, 2009, Pages 343-353

  Barnett, Anthony H ^a,b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INCRETIN; LIRAGLUTIDE; MEGLITINIDE; METFORMIN; PIOGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; VILDAGLIPTIN;

BLISTER; CLINICAL TRIAL; DIZZINESS; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERANCE; EVENING DOSAGE; FOOD INTAKE; GLUCAGON RELEASE; GLYCEMIC CONTROL; HEADACHE; HEPATITIS; HUMAN; INFLUENZA; INSULIN RELEASE; MORNING DOSAGE; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REVIEW; RHINOPHARYNGITIS; RISK REDUCTION; SKIN ULCER; STOMACH EMPTYING; UPPER RESPIRATORY TRACT INFECTION; WEIGHT REDUCTION;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIA; INCRETINS; INSULIN; RISK FACTORS; WEIGHT LOSS;

EID: 60349099802     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2008.03396.x     Document Type: Review

References (108)

1. IDF Clinical Guidelines Task Force 2006) Global guideline for type 2 diabetes: recommendations for standard, comprehensive, and minimal care. Diabetic Medicine, 23, 579 593.
2. Gungor, N. Arslanian, S. (2002) Pathophysiology of type 2 diabetes mellitus in children and adolescents: treatment implications. Treatments in Endocrinology, 1, 359 371.
3. Diabetes Control Complications Trial Research Group 1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The New England Journal of Medicine, 329, 977 986.
4. Reichard, P., Nilsson, B.Y. Rosenqvist, V. (1993) The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. The New England Journal of Medicine, 329, 304 309.
5. Malmberg, K. (1997) Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. British Medical Journal, 314, 1512 1515.
6. UKPDS Group 1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 352, 837 853.
7. Shichiri, M., Kishikawa, H., Ohkubo, Y. et al. (2000) Long-term results of the Kumamoto Study on Optimal Diabetes Control in type 2 diabetic patients. Diabetes Care, 23 (Suppl. 2 B21 29.
8. Weyer, C., Tataranni, P.A., Bogardus, C. et al. (2001) Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care, 24, 89 94.
9. Kahn, S.E. (2000) The importance of the β-cell in the pathogenesis of type 2 diabetes mellitus. American Journal of Medicine, 108 (Suppl. 6a 2S 8S.
10. UK Prospective Diabetes Study (UKPDS) Group 1995) UK prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes, 44, 1249 1258.
11. Nesto, R.W. (2003) The relation of insulin resistance syndromes to risk of cardiovascular disease. Reviews in Cardiovascular Medicine, 4 (Suppl. 6 S11 S18.
12. Smiley, T., Oh, P. Shane, L.G. (2001) The relationship of insulin resistance measured by reliable indexes to coronary artery disease risk factors and outcomes - a systematic review. The Canadian Journal of Cardiology, 17, 797 805.
13. Bonora, E., Formentini, G., Calcaterra, F. et al. (2002) HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabetes Care, 25, 1135 1141.
14. Barnett, A.H., Dixon, A.N., Bellary, S. et al. (2006) Type 2 diabetes and cardiovascular risk in the UK south Asian community. Diabetologia, 49, 2234 2246.
15. Monnier, L., Lapinski, H. Colette, C. (2003) Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA (1c). Diabetes Care, 26, 881 885.
16. Esposito, K., Giugliano, D., Nappo, F. et al. (2004) Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation, 110, 214 219.
17. Perley, M.J. Kipnis, D.M. (1967) Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. The Journal of Clinical Investigation, 46, 1954 1962.
18. Orskov, C., Wettergrena, A. Holst, J.J. (1993) Biological effects and metabolic rates of glucagonlike peptide-1, 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable. Diabetes, 42, 658 661.
19. Baggio, L.L. Drucker, D.J. (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology, 132, 2131 2157.
20. Vilsboll, T., Krarup, T., Deacon, C.F. et al. (2001) Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes, 50, 609 613.
21. Nauck, M.A., Heimesaat, M.M., Orskov, C. et al. (1993) Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. The Journal of Clinical Investigation, 91, 301 307.
22. Drucker, D.J. (2001) Minireview: the glucagon-like peptides. Endocrinology, 142, 521 527.
23. Zander, M., Madsbad, S., Madsen, J.L. et al. (2002) Effect of 6 week course of glucagon like peptide 1 on glycaemic control, insulin sensitivitiy, (-cell function in type 2 diabetes: a parallel group study. Lancet, 359, 824 830.
24. Parkes, D.G., Pittner, R., Jodka, C. et al. (2001) Insulinotropic actions of exendin 4 and glucagon like peptide 1 in vivo and in vitro. Metabolism, 50, 583 589.
25. Goke, R., Fehmann, H.C., Linn, T. et al. (1993) Exendin-4 is a high potency agonist and truncated exendin (9-39) - amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting β-cells. The Journal of Biological Chemistry, 268, 19650 19655.
26. Delmeire, D., Flamez, D., Moens, K. et al. (2003) Prior in vitro exposure to GLP-1 with or without GIP can influence the subsequent β cell responsiveness. Biochemical Pharmacology, 68, 33 39.
27. Nauck, M.A., Holst, J.J., Willms, B. et al. (1997) Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2 diabetes. Experimental and Clinical Endocrinology and Diabetes, 105, 187 195.
28. Perfetti, R. Merkel, P. (2000) Glucagon-like peptide-1: a major regulator of pancreatic β-cell function. European Journal of Endocrinology, 143, 717 725.
29. Drucker, D.J., Philippe, J., Mojsov, S. et al. (1987) Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proceedings of the National Academy of Sciences of USA, 84, 3434 3438.
30. Holst, J.J. (2002) Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes Metabolism Research Review, 18, 430 441.
31. Rayner, C.K., Samsom, M., Jones, K.L. et al. (2001) Relationships of upper gastrointestinal motor and sensory function with glycemic control. Diabetes Care, 24, 371 381.
32. Flint, A., Raben, A., Astrup, A. et al. (1998) Glucagon-like peptide 1 promotes satiety and suppresses energy intakes in humans. Journal of Clinical Investigation, 101, 515 520.
33. Naslund, E., Barkeling, B., King, N. et al. (1999) Energy intake and appetite are suppressed by glucagon-like peptide 1 (GLP-1) in obese men. International Journal of Obesity and Related Metabolic Disorders, 23, 304 311.
34. Gutzwiller, J.P., Drewe, J., Goke, B. et al. (1999) Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. The American Journal of Physiology, 276, 1541 1544.
35. Gautier, J.F., Fetita, S., Sobngwi, E. et al. (2005) Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes. Diabetes and Metabolism, 31, 233 242.
36. Parkes, D., Jodka, C., Smith, P. et al. (2001) Pharmacokinetic actions of exendin-4 in the rat: comparison with glucagon-like peptide-1. Drug Development Research, 53, 260 267.
37. Greig, N.H., Holloway, H.W., De Ore, K.A. et al. (1999) Once daily injections of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations. Diabetologia, 42, 45 50.
38. Young, A.A., Gedulin, B.R., Bhavsar, S. et al. (1999) Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes, 48, 1026 1034.
39. Patsch, J.R., Miesenbock, G. Hopferweiser, T. (1992) Relation of triglyceride metabolism and coronary artery disease to studies in the postprandial state. Arterioscler Thrombosis, 12, 1336 1345.
40. Fehse, F., Trautmann, M., Holst, J.J. et al. (2005) Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism, 90, 5991 5997.
41. Baron, A.D., Schaeffer, L., Shragg, P. et al. (1987) Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes, 36, 274 283.
42. Kolterman, O.G., Buse, J.B., Fineman, M.S. et al. (2003) Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism, 88, 3082 3089.
43. Kolterman, O.G., Kim, D.D., Shen, L. et al. (2005) Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. American Journal of Health-System Pharmacy, 62, 173 181.
44. Edwards, C.M., Stanley, S.A., Davis, R. et al. (2001) Exendin 4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. American Journal of Physiology Endocrinology and Metabolism, 281, E155 E161.
45. Gedulin, B.R., Nikoulina, S.E., Smith, P.A. et al. (2005) Exenatide (exendin-4) improves insulin sensitivity (-cell mass in insulin-resistant obese Fa/Fa Zucker rats independent of glycemia and body weight. Endocrinology, 146, 2069 76.
46. Xu, G., Stoffers, D.A., Habener, J.F. et al. (1999) Exendin-4 stimulates both β-cell replication and neogenesis, resulting in increased β-cell mass and improved glucose tolerance in diabetic rats. Diabetes, 48, 2270 2276.
47. Tourrel, C., Bailbé, D., Lacorne, M. et al. (2002) Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the β-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. Diabetes, 51, 1443 1452.
48. Tourrel, C., Bailbé, D., Meile, M.J. et al. (2001) Glucagon-like peptide-1 and exendin-4 stimulate β-cell neogenesis in streptozotocin- treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes, 50, 1562 1570.
49. Stoffers, D.A., Desai, B.M., DeLeon, D.D. et al. (2003) Neonatal exendin-4 prevents the development of diabetes in the intrauterine growth retarded rat. Diabetes, 52, 734 740.
50. Fineman, M.S., Bicsak, T.A., Shen, L.Z. et al. (2003) Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care, 26, 2370 2377.
51. Buse, J.B., Henry, R.R., Han, J. et al. (2004) Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care, 27, 2628 2635.
52. DeFronzo, R.A., Ratner, R.E., Han, J. et al. (2005) Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care, 28, 1092 1100.
53. Kendall, D.M., Riddle, M.C., Rosenstock, J. et al. (2005) Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care, 28, 1083 1091.
54. Kim, D., MacConell, L., Zhuang, D. et al. (2007) Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care, 30, 1487 1493.
55. Klonoff, D.C., Buse, J.B., Nielsen, L.L. et al. (2008) Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Current Medical Research and Opinions, 24, 275 286.
56. Barnett, A.H., Burger, J., Johns, D. et al. (2007) Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clinical Therapy, 29, 2333 2348.
57. Fineman, M.S., Shen, L.Z., Taylor, K. et al. (2004) Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side-effects in subjects with type 2 diabetes. Diabetes Metabolism Research Review, 20, 411 417.
58. Byetta® Summary of Product Characteristics. Eli Lilly Company Limited (28 January 2008). Available at : http://www.medicines.org.uk/emc.aspx (Accessed April 2008).
59. Agerso, H., Jensen, L.B., Elbrond, B. et al. (2002) The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia, 45, 195 202.
60. Irie, S., Matsumura, Y., Zdravkovic, M. et al. (2008) Tolerability, pharmacokinetics and pharmacodynamics of the once-daily human GLP-1 analog liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo-controlled dose-escalation study. International Journal of Clinical Pharmacology, Therapeutics, 46, 273 279.
61. Juhl, C.B., Hollingdal, M., Sturis, J. et al. (2002) Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes, 51, 424 429.
62. Knudsen, L.B., Nielsen, P.F., Huusfeldt, P.O. et al. (2000) Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. Journal of Medical Chemistry, 43, 1664 1669.
63. Degn, K.B., Juhl, C.B., Sturis, J. et al. (2004) One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and α- and β-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes, 53, 1187 1194.
64. Bregenholt, S., Møldrup, A., Blume, N. et al. (2005) The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits β-cell apoptosis in vitro. Biochemical and Biophysical Research Communications, 330, 577 584.
65. Vilsbøll, T., Brock, B., Perrild, H. et al. (2008) Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. Diabetic Medicine, 25, 152 156.
66. Vilsbøll, T., Zdravkovic, M., Le-Thi, T. et al. (2007) Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care, 30, 1608 1610.
67. Seino, Y., Rasmussen, M.F., Zdravkovic, M. et al. (2008) Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: a double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes. Diabetes Research and Clinical Practice, 81, 161 168.
68. Marre, M., Shaw, J., Brandle, M. et al. (2008) Liraglutide, a once-daily Human GLP-1 analog, added to a sulfonylurea (SU) offers significantly better glycemic control and favorable weight change compared with rosiglitazone and SU combination therapy in subjects with type 2 diabetes. Presented at American Diabetes Association 68th Scientific Sessions, 6-10 June 2008, San Francisco, California. Abstract 13-OR.
69. Garber, A., Henry, R., Ratner, R. et al. (2008) Significantly better glycemic control and weight reduction with liraglutide, a once-daily human GLP-1 analog, compared with glimepiride: all as monotherapy in type 2 diabetes. Presented at American Diabetes Association 68th Scientific Sessions, 6-10 June 2008, San Francisco, California. Abstract 07-LB.
70. Nauck, M.A., Frid, A., Hermansen, K. et al. (2008) Liraglutide, a once-daily human GLP-1 analog, in type 2 diabetes provides similar glycemic control with reduced body weight compared with glimepiride when added to metformin. Presented at American Diabetes Association 68th Scientific Sessions, 6-10 June 2008, San Francisco, California. Abstract 504-P.
71. Russell-Jones, D., Vagg, A., Schmitz, O. et al. (2008) Significantly better glycemic control and weight reduction with liraglutide, a once-daily human GLP-1 analog, compared with insulin glargine: all as add-on to metformin and a sulfonylurea in type 2 diabetes. Presented at American Diabetes Association 68th Scientific Sessions, 6-10 June 2008, San Francisco, California. Abstract 536-P.
72. Lambeir, A.M., Durinx, C., Scharpe, S. et al. (2003) Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Critical Reviews in Clinical Laboratory Sciences, 40, 209 294.
73. Mentlein, R. (1999) Dipeptidyl-peptidase IV (CD26) - role in the inactivation of regulatory peptides. Regulatory peptides, 85, 9 24.
74. Kieffer, T.J., McIntosh, C.H. Pederson, R.A. (1995) Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology, 136, 3585 3596.
75. Ahren, B., Landin-Olsson, M., Jansson, P.A. et al. (2004) Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. The Journal of Clinical Endocrinology and Metabolism, 89, 2078 2084.
76. Abbott, C.A., Yu, D.M., Woollatt, E. et al. (2000) Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8. European Journal of Biochemistry, 267, 6140 6150.
77. Olsen, C. Wagtmann, N. (2002) Identification and characterization of human DPP9, a novel homologue of dipeptidyl peptidase IV. Gene, 299, 185 193.
78. Villhauer, E.B., Brinkman, J.A., Naderi, G.B. et al. (2003) 1-[[(3-hydroxy-1-adamantyl) amino-]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. Journal of Medical Chemistry, 46, 2774 2789.
79. Brandt, I., Joossens, J., Chen, X. et al. (2005) Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by Vildagliptin (2S)-[(3-hydroxyadamantan-1-yl) amino]acetyl-pyrrolidine-2-carbonitrile). Biochemical Pharmacology, 70, 134 143.
80. Weber, A.E., Kim, D., Beconi, M. et al. (2004) MK-0431 is a potent, selective, dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Diabetes, 633-P, Abstract.
81. Augeri, D.J., Robl, J.A., Betebenner, D.A. et al. (2005) Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Journal of Medical Chemistry, 48, 5025 5037.
82. Kim, Y.B., Kopcho, L.M., Kirby, M.S. et al. (2006) Mechanism of Gly-Pro-pNA cleavage catalyzed by dipeptidyl peptidase-IV and its inhibition by saxagliptin (BMS-477118). Archives of Biochemistry and Biophysics, 445, 9 18.
83. Ahren, B., Holst, J.J., Martensson, H. et al. (2000) Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. European Journal of Pharmacology, 404, 239 245.
84. Pederson, R.A., White, H.A., Schlenzig, D. et al. (1998) Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes, 47, 1253 1258.
85. Balkan, B., Kwasnik, L., Miserendino, R. et al. (1999) Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia, 42, 1324 1331.
86. Herman, G.A., Bergman, A., Liu, F. et al. (2006) Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. Journal of Clinical Pharmacology, 46, 876 886.
87. Pospisilik, J.A., Martin, J., Doty, T. et al. (2003) Dipeptidyl peptidase IV inhibitor treatment stimulates β-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes, 52, 741 750.
88. Pospisilik, J., Stafford, S., Demuth, H.-U. et al. (2002) Long-term treatment with the DP IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia β-cell glucose responsiveness in VDF (fa/fa) Zucker Rats. Diabetes, 51, 943 950.
89. Bergman, A.J., Stevens, C., Zhou, Y. et al. (2006) Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clinical Therapeutics, 28, 55 72.
90. Mari, A., Sallas, W.M., He, Y.L. et al. (2005) Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism, 90, 4888 4894.
91. Ahren, B., Simonsson, E., Larsson, H. et al. (2002) Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care, 25, 869 875.
92. He, Y.L., Serra, D., Wang, Y. et al. (2007) Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus. Clinical Pharmacokinetics, 46, 577 588.
93. Charbonnel, B., Karasik, A., Liu, J. et al. (2006) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care, 29, 2638 2643.
94. Goldstein, B.J., Feinglos, M.N., Lunceford, J.K. et al. (2007) Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care, 30, 1979 1987.
95. Rosenstock, J., Brazg, R., Andryuk, P.J. et al. (2006) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clinical Therapeutics, 28, 1556 1568.
96. Nauck, M.A., Meininger, G., Sheng, D. et al. (2007) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes, Obesity and Metabolism, 9, 194 205.
97. Hermansen, K., Kipnes, M., Luo, E. et al. (2007) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes, Obesity and Metabolism, 9, 733 745.
98. Scott, R., Wu, M., Sanchez, M. et al. (2007) Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. International Journal of Clinical Practice, 61, 171 180.
99. Raz, I., Hanefeld, M., Xu, L. et al. (2006) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia, 49, 2564 2571.
100. Januvia® Summary of Product Characterisitics. Merck Sharp Dohme Limited (26 February 2008). Available at : http://www.medicines.org.uk (Accessed April 2008).
101. Bosi, E., Camisasca, R.P., Collober, C. et al. (2007) Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care, 30, 890 895.
102. Garber, A.J., Schweizer, A., Baron, M.A. et al. (2007) Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes, Obesity and Metabolism, 9, 166 174.
103. Rosenstock, J., Baron, M.A., Dejager, S. et al. (2007) Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care, 30, 217 223.
104. Rosenstock, J., Baron, M.A., Camisasca, R.P. et al. (2007) Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 9, 175 185.
105. Pi-Sunyer, F.X., Schweizer, A., Mills, D. et al. (2007) Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes. Diabetes Research and Clinical Practice, 76, 132 138.
106. Galvus®. Summary of Product Characterisitics. Novartis Pharmaceuticals UK Ltd (20 February 2008). Available at: http://www.medicines. org.uk (Accessed April 2008).
107. Drucker, D.J. Nauck, M.A. (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet, 368, 1696 1705.
108. Salehi, M. D'Alessio, D.A. (2006) New therapies for type 2 diabetes based on glucagon-like peptide 1. Cleveland Clinic Journal of Medicine, 73, 382 389.